Trials / Completed
CompletedNCT00529802
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
An Exploratory Study Evaluating FDG-PET as a Predictive Marker for mTOR Directed Therapy With RAD001 in Metastatic Renal Cell Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn if PET scanning can predict the degree of tumor shrinkage with the study drug RAD001 in subjects who have advanced renal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RAD001 | take 2 tablets of RAD001 once a day by mouth (10 mg per day) |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2007-09-14
- Last updated
- 2018-04-25
- Results posted
- 2017-11-09
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00529802. Inclusion in this directory is not an endorsement.